Second cancer risk in hairy cell leukemia : Analysis of 350 patients.
The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of long-term outcome.
We have therefore examined the incidence of second cancers.
Patients and Methods
Data on 350 HCL patients was obtained from the M.D. Anderson Cancer Center Cancer Registry's computerized data base and from chart review.
Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) (observed/expected [O/E]) were calculated with the expected number determined using age, sex, and calendar-year-specific rates from the Connecticut Tumor Registry and from national mortality data, respectively.
The median age of the patients was 50 years and the median follow-up duration was 6 years.
Twenty-six patients developed a second cancer at least 6 months after the HCL diagnosis (O/E ratio, 1.34 ; P=08).
There was no excess of malignancy among patients treated with interferon alfa (IFN-alpha ; P=27), 2-chlorodeoxyadenosine (2CDA ; P=37), or deoxycoformycin (DCF ; P=7).
However, an excess of myeloma-related neoplasms (O/E, 13.04 ; P<. 001) and lymphomas (O/E, 8.7 ; P=03) was observed.
Survival from the advent of systemic therapy for HCL was better than before this time (P=0009).
Nevertheless, mortality remained excessive (O/E, 6.17 ; P<. 001), mainly because of HCL-related infections and secondary malignancy. (...)
Mots-clés Pascal : Leucémie lymphohistiocytaire, Homme, Second cancer, Epidémiologie, Incidence, Etude longitudinale, Etude cohorte, Complication, Chronique, Hémopathie maligne, Lymphoprolifératif syndrome, Tumeur maligne
Mots-clés Pascal anglais : Hairy cell leukemia, Human, Second cancer, Epidemiology, Incidence, Follow up study, Cohort study, Complication, Chronic, Malignant hemopathy, Lymphoproliferative syndrome, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0299758
Code Inist : 002B19B. Création : 15/07/1997.